Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136522 | 0.90 | USP30 (0.46) | USP30KDM2BAKR1C3DRD3CYP11B2 | |
| SCHEMBL4141749 | 0.88 | MLNR (0.37) | KDM2BKDM4EALDH1A1NPSR1DRD2 | |
| SCHEMBL4130700 | 0.87 | ALDH1A1 (0.39) | KDM4EALDH1A1DRD2DRD3 | |
| SCHEMBL4136207 | 0.83 | USP30 (0.42) | USP30KDM2BKCNH2DRD3CYP1A2 | |
| SCHEMBL4141043 | 0.83 | KDM2B (0.38) | USP30KDM2BDRD2DRD3CYP1A2 | |
| SCHEMBL4139662 | 0.81 | PNMT (0.35) | KDM4EALDH1A1NPSR1DRD2DRD3 | |
| SCHEMBL4141084 | 0.81 | JAK2 (0.42) | KDM2BKCNH2HRH3KDM4EALDH1A1 | |
| SCHEMBL4128188 | 0.80 | KCNH2 (0.39) | KCNH2HRH3DRD2DRD3 | |
| SCHEMBL4136604 | 0.80 | KDM2B (0.42) | USP30KDM2BHRH3ALDH1A1DRD3 | |
| SCHEMBL4136716 | 0.80 | HDAC4 (0.38) | KDM4EALDH1A1NPSR1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | USP30 3191/4885KDM2B 3965/4885KCNH2 657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.